Overview
The current study is a phase II multi-center single arm trial to evaluate the efficacy and safety of adding Anti-PD-1 antibody in an inductive and concurrent way to radiotherapy in early-stage low-risk extranodal NK/T cell lymphoma, nasal type
Eligibility
Inclusion Criteria:
- Biopsy proved extranodal NK/T cell lymphoma
- No previous anti-cancer treatment
- Measurable lesion on baseline PET/CT and MRI
- Stage I
- Normal serum LDH level
- Primary tumor invasion (PTI) absence
- ECOG PS 0-1
- Sufficient organ functions
Exclusion Criteria:
- Other mature T- or NK- lymphoma
- Hemophagocytic lymphohistiocytosis
- Primary CNS lymphoma or CNS-involved lymphoma
- History of malignancy except for cutaneous basal-/squamous- cell carcinoma or cervical carcinoma in situ 3 years prior to study treatment
